Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD


April 28, 2023

Figure 1. Glucagon-like peptide 1 (GLP-1, 7-36) molecule. GLP-1 analogues are used in the treatment of diabetes.

Guidelines from the American Association of Clinical Endocrinology recommend considering glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in addition to metformin for patients who have not reached their glycemic target. Initial combination therapy may also be considered in patients with type 2 diabetes presenting with A1c levels 1.5%-2.0% above target. Research has shown that GLP-1 RAs are the most effective non-insulin agent in reducing hemoglobin A1c in patients with uncontrolled type 2 diabetes. Incretin-based therapy can also be considered in patients with contraindications to metformin, such as in those with renal dysfunction.

Learn more about pharmacologic therapy for type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.